Barinthus Biotherapeutics (BRNS) provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease. Strategic Business Focus and Restructuring: The Company will prioritize and Inflammation, I&I, indications, including antigen-specific immune tolerance. The Company plans to extend the cash runway to the start of 2027 by reducing costs, including a reduction in headcount by approximately 65% across both sites, and streamlining the operating costs of the business. The Company will not invest in VTP-300 in chronic hepatitis B beyond the completion of the ongoing Phase 2b HBV003 clinical trial and will seek potential partners able to take advantage of its differentiated ability to achieve sustained HBsAg loss and functional cure in patients with low levels of HBsAg. Financial Update: Cash, cash equivalents and restricted cash are expected to be $112 million as of December 31, 2024.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Biotherapeutics Appoints New Chief Scientific Officer
- Barinthus CSO Nadege Pelletier to depart, Geoffrey Lynn to succeed
- Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
- Barinthus announces results from ongoing Phase 2b HBV003 trial
- Arbutus and Barinthus announce new data from IM-PROVE II trial